)
Inogen (INGN) investor relations material
Inogen Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 continuing-operations revenue was $77.193M, down 2.4% YoY; adjusted net loss was $0.4M versus adjusted earnings of $1.2M a year earlier.
U.S. sales returned to YoY growth for the first time since Q4 2024, while lower international sales offset the increase.
Andy Reding became President and CEO; priorities include commercial execution, growth products, and disciplined costs.
The U.S. oxygen rental business was sold after quarter-end, with a post-sale program targeting $20M in annualized savings by end-2027.
Financial highlights
Q3 revenue was $77.193M versus $79.090M a year earlier; constant-currency revenue declined 3.2%.
GAAP loss from continuing operations was $14.794M versus $3.6M in Q3 2025, including a $10.559M non-cash goodwill impairment.
Adjusted diluted loss per share was $0.02 versus adjusted earnings per share of $0.04; adjusted operating loss was $1.2M versus $0.6M.
Nine-month revenue rose 2.8% to $233.122M; GAAP loss from continuing operations was $25.4M and adjusted loss was $2.9M.
Q3 operating cash flow was negative $4.5M due to higher working capital; nine-month continuing-operations cash used was $13.610M, improved from $20.398M.
Outlook and guidance
Q4 2026 continuing-operations revenue guidance is $65M-$68M; FY 2026 guidance is $298M-$301M.
FY 2026 adjusted loss from continuing operations is expected to be $7M-$8M; adjusted net earnings replaces adjusted EBITDA after the divestiture.
International softness is expected to continue into Q4, with U.S. growth projected to accelerate and offset some weakness.
Savings program targets ~$20M annualized, with about half expected in Q4 2026 and the balance during 2027; substantial completion is expected by end-2027.
- FY25 adjusted EBITDA turned positive as the respiratory portfolio expanded into new markets.INGN
Corporate presentation - Q2 2026 revenue up 3% to $95.1M, with strong international growth and improved EBITDA.INGN
Q2 2026 - Achieved a financial turnaround and expanded into new respiratory care markets with innovative products.INGN
Corporate presentation - Diversified platform, new products, and financial turnaround position for sustained growth.INGN
Corporate presentation - Directors, auditors, and compensation approved; board declassification amendment failed.INGN
AGM 2026 - Revenue up 3.4% to $85.1M, driven by international growth despite higher net loss.INGN
Q1 2026 - Proxy details director elections, governance reforms, and expanded equity incentives for 2026.INGN
Proxy filing - Shareholders will vote on board declassification, equity plan expansion, and key governance changes.INGN
Proxy filing - New products and leadership drive growth, margin expansion, and strategic transformation.INGN
25th Annual Needham Virtual Healthcare Conference
)
)
)
)
)
)
)
)